NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-24 pm EST			5-day change	1st Jan Change
26.33 ^USD	-2.55%		+0.61%	-11.64%

Dec. 02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
Dec. 02	NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint	MT

NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024

October 30, 2024 at 07:00 am EDT

NovoCure Limited reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was USD 155.1 million compared to USD 127.32 million a year ago. Net loss was USD 30.57 million compared to USD 49.49 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.46 a year ago. Diluted loss per share from continuing operations was USD 0.28 compared to USD 0.46 a year ago.
For the nine months, sales was USD 443.95 million compared to USD 375.55 million a year ago. Net loss was USD 102.71 million compared to USD 159.96 million a year ago. Basic loss per share from continuing operations was USD 0.95 compared to USD 1.51 a year ago. Diluted loss per share from continuing operations was USD 0.95 compared to USD 1.51 a year ago.

Latest news about NovoCure Limited

HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	Dec. 02	MT
NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint	Dec. 02	MT
Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating	Dec. 02	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Dec. 02	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of Week Promising Crucial Economic Data	Dec. 02	MT
Zai Lab, NovoCure Say Pancreatic Cancer Trial Meets Primary Endpoint	Dec. 02	MT
Evercore ISI Upgrades NovoCure to Outperform	Dec. 02	MT
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy for Pancreatic Cancer	Dec. 02	CI
NovoCure Gets FDA Nod for Updated Optune Gio Arrays	Nov. 21	MT
Novocure FDA Approves Novocure?S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma	Nov. 21	CI
NovoCure Names New Chief Financial Officer	24-10-30	MT
NovoCure Q3 Loss Narrows, Net Revenue Increases	24-10-30	MT
NovoCure Limited, Q3 2024 Earnings Call, Oct 30, 2024	24-10-30
Earnings Flash (NVCR) NOVOCURE Posts Q3 Revenue $155.1M	24-10-30	MT
Earnings Flash (NVCR) NOVOCURE Posts Q3 Loss $-0.28	24-10-30	MT
Earnings Flash (NVCR) NOVOCURE Posts Q3 Loss $-0.28 Per Share	24-10-30	MT
NovoCure Limited Appoints Christoph Brackmann as Senior Financial Advisor	24-10-30	CI
NovoCure Limited Announces CFO Appointment	24-10-30	CI
NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	24-10-30	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Big Banks Gather Investors' Confidence	24-10-16	MT
Sector Update: Health Care Stocks Rise Premarket Wednesday	24-10-16	MT
Wall Street Consolidates After ASML-Fueled Losses as US Equity Futures Tread Water Pre-Bell	24-10-16	MT
Sector Update: Health Care	24-10-16	MT
Top Premarket Gainers	24-10-16	MT
HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24	24-10-16	MT

Chart NovoCure Limited

Duration

Period

NVCR: Dynamic Chart

Company Profile

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Employees

1,453

Sector

Medical Equipment, Supplies & Distribution

Calendar

2025-02-27 - Q4 2024 Earnings Release

More about the company